The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

TP53 Mutations in MDS: Is Combination of Eprenetapopt + AZA Well-Tolerated in Patients With TP53-Mutant MDS & Oligoblastic AML? What Are the Rates of Clinical Response & Molecular Remissions?

112 views
March 5, 2021
0 Comments
Login to view comments. Click here to Login
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases